港股異動 | 君實生物(1877.HK)大漲超10%創歷史新高 市值超600億港元
格隆匯1月19日丨君實生物(1877.HK)今日續漲,暫六日連升累漲超35%,現漲10.65%報74.8港元,股價續創歷史新高,暫成交7197萬港元,最新總市值652億港元,該股去年累漲112.73%,今年迄今已累漲超31%。君實生物(688180.SH)亦漲超5%。瑞銀近日發研報指,恢復覆蓋君實生物,指其核心產品PD-1被納入2020年國家醫保藥品目錄(NRDL),有助於促進醫院上市。通過內部研發及許可,公司建立了強大的渠道,可支持長遠增長。該行上調其2020至2022年每股盈利預測,並予公司“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.